Introduction {#s1}
============

Toll-like receptors (TLRs) recognize conserved microbial features and initiate signals critical for induction of immune responses to infection. A subset of TLRs (TLR3, TLR7, TLR8, and TLR9) recognizes forms of nucleic acids, including double-stranded RNA, single-stranded RNA, and DNA ([@bib4]). This specificity facilitates recognition of a broad array of microbes but introduces the potential for recognition of self-nucleic acids. TLR7 and TLR9 recognition of self-RNA and self-DNA, respectively, contributes to autoimmune diseases such as systemic lupus erythematosus (SLE) ([@bib37]; [@bib16]).

Discrimination between self and microbial nucleic acids cannot be achieved solely through recognition of distinct features but instead relies on differential delivery of these potential ligands to TLRs ([@bib6]). All of the TLRs capable of nucleic acid recognition localize within endosomal compartments which sequesters these receptors away from self nucleic acids in the extracellular space ([@bib6]). Our previous studies as well as work from other groups indicate that a requirement for ectodomain cleavage of intracellular TLRs further restricts receptor activation to protease-rich acidic compartments ([@bib22], [@bib21]; [@bib48]; [@bib25]). Bypassing this requirement enables responses to extracellular self nucleic acid and leads to fatal inflammatory disease in mice ([@bib42]). Moreover, the system appears carefully balanced as simply overexpressing TLR7 in mice causes responses to self-RNA and development of an SLE-like disease ([@bib50]; [@bib58]; [@bib19]). Thus, defining the regulatory steps that control TLR localization and influence the threshold of receptor activation has important implications for self/non-self discrimination.

TLR9 and other intracellular TLRs must traffic from the endoplasmic reticulum (ER) to endolysosomes before responding to ligands. UNC93B1, a multi-pass transmembrane protein localized to the ER, appears to facilitate this trafficking ([@bib11]; [@bib32]). Mice homozygous for a nonfunctional Unc93b1 (H412R) allele (*Unc93b1*^3d/3d^) fail to respond to TLR3, TLR7, or TLR9 ligands, and mice and humans deficient in UNC93B1 are highly susceptible to viral infection ([@bib13]; [@bib59]; [@bib34]). More recently, UNC93B1 has been implicated in the function of TLR11, TLR12, and TLR13 ([@bib49]; [@bib55]; [@bib33]; [@bib47]). UNC93B1 is not required for responses by surface localized TLRs such as TLR2 and TLR4 ([@bib59]). UNC93B1 associates with endosomal TLRs, and in cells with defective UNC93B1, TLR9 and TLR7 fail to leave the ER ([@bib11]; [@bib32]). However, the mechanism by which UNC93B1 facilitates TLR trafficking to endosomal compartments remains enigmatic, especially considering its reported direct translocation from the ER to endolysosomes ([@bib32]). This pathway is inconsistent with our findings that TLR9 and TLR7 traffic through the general secretory pathway en route to endosomes ([@bib22], [@bib21]). In addition, mice expressing an aspartic acid to alanine mutation at amino acid position 34 in UNC93B1 (*Unc93b1*^D34A/D34A^) were recently shown to develop spontaneous autoimmunity due to enhanced TLR7 responses and diminished TLR9 responses ([@bib24], [@bib23]). These findings suggest that regulation of TLRs by UNC93B1 can influence the relative thresholds of receptor activation. For these reasons, we have sought to define the molecular basis by which UNC93B1 controls endosomal TLR trafficking and function.

Beyond the implied role for UNC93B1 discussed above, little is known about the molecular mechanisms that mediate proper localization of endosomal TLRs and no other factor required specifically for endosomal TLR trafficking has been identified. Nevertheless, several reports suggest that endosomal TLR trafficking may be influenced at both ER and post-Golgi trafficking steps. Gp96 functions as an ER folding chaperone for many TLRs, including TLR9, and PRAT4A has been implicated in TLR trafficking from the ER ([@bib60]; [@bib63]; [@bib35]). Additionally, the HRS/ESCRT pathway is involved in post-Golgi trafficking by sorting ubiquitinated TLR7 and TLR9 to endosomal compartments ([@bib15]), and the adaptor protein-3 (AP-3) has been reported to target TLR9 and TLR7 to lysosome related organelles specialized for type I IFN induction ([@bib27]; [@bib9]; [@bib54]). Interestingly, UNC93B1 trafficking to these compartments is also impaired in AP-3 deficient cells ([@bib54]). Whether UNC93B1 interacts with other components implicated in trafficking of endosomal TLRs remains to be determined.

In this study, we report that UNC93B1 is required for multiple steps of TLR trafficking. UNC93B1 plays a direct role in facilitating exit of TLRs from the ER as well as a later role in recruitment of adaptor protein-2 (AP-2) to facilitate endocytosis of TLR9 from the plasma membrane. Surprisingly, TLR7 does not have the same requirements for UNC93B1 and utilizes distinct trafficking machinery to reach endolysosomes. Thus, our results describe how UNC93B1 controls endosomal TLR trafficking and provide the first mechanistic basis for differential regulation of these receptors.

Results {#s2}
=======

UNC93B1 traffics to phagosomes via the Golgi compartment {#s2-1}
--------------------------------------------------------

UNC93B1 has been described as an ER-resident trafficking chaperone that translocates TLRs directly from the ER to endolysosomes upon TLR activation ([@bib32]). This model is based in part on the observation that UNC93B1 never acquires Endoglycosidase H (EndoH)-resistant glycans ([@bib11]), which are acquired only when proteins traffic through the medial Golgi. Because this proposed function for UNC93B1 conflicts with our model of TLR9 trafficking ([@bib22], [@bib21]), we first examined whether UNC93B1 is present in endolysosomal compartments in unstimulated cells. Wildtype (WT) UNC93B1 but not the nonfunctional (H412R) mutant was detectable in phagosomes purified from unstimulated RAW264 cells ([Figure 1A](#fig1){ref-type="fig"}). Moreover, a portion of UNC93B1-WT gained EndoH-resistance in multiple cell types, while UNC93B1-H412R was entirely EndoH-sensitive ([Figure 1B--F](#fig1){ref-type="fig"}). These results agree with a previous report that the H412R mutant fails to leave the ER ([@bib32]). To formally demonstrate that the increased molecular weight of UNC93B1-WT is due to N-linked glycans, we mutated Asn-251, which is within a consensus N-glycosylation site, and this mutant failed to acquire EndoH-resistant glycans ([Figure 1G](#fig1){ref-type="fig"}). Based on the acquisition of EndoH-resistant glycans by UNC93B1, we examined whether UNC93B1 is detectable within COPII vesicles, which mediate transport of cargo between the ER and Golgi ([@bib65]). Using an in vitro COPII budding assay ([@bib31]; [@bib41]), we compared levels of UNC93B1-WT and UNC93B1-H412R in purified vesicles. UNC93B1-WT, but not H412R, was clearly present within the vesicles, further supporting a model in which UNC93B1 exits the ER through the general secretory pathway ([Figure 1H](#fig1){ref-type="fig"}). Altogether, these data indicate that a pool of UNC93B1 protein exits the ER and traffics through the Golgi in unstimulated cells. Moreover, transit from the ER to the Golgi may be important for UNC93B1 function, as the nonfunctional UNC93B1-H412R mutant fails to enter COPII vesicles and does not reach the medial Golgi.10.7554/eLife.00291.003Figure 1.UNC93B1 traffics to the Golgi en route to endolysosomes.(**A**) UNC93B1 is present in phagolysosomes of unstimulated cells. Phagosomes (PHG) isolated by flotation from RAW264 cells only (Ø) or expressing GFP tagged UNC93B1-WT or UNC93B1-H412R and cells prior to isolation (Pre) were separated by SDS-PAGE, and immunoblotted with anti-GFP, anti-LAMP1 (lysosome marker), and anti-calnexin (ER marker). (**B**) A portion of UNC93B1 protein traffics to the Golgi apparatus. Wildtype UNC93B1 (WT) or H412R, each with a C-terminal 3× FLAG tag, were expressed in HEK293Ts by transient transfection. The immunoprecipitated proteins were treated with EndoH (E), PNGaseF (P) or left untreated (−), separated by SDS-PAGE, and visualized by immunoblot with anti-FLAG antibody. Bands representing EndoH-sensitive (white arrow) and resistant (black arrow) forms of UNC93B1 are indicated. (**C**)--(**F**) UNC93B1 acquires EndoH-resistant modifications. UNC93B1 tagged with GFP (**C**) or myc-His (**D**) from transiently transfected HEK293Ts, and FLAG tagged UNC93B1 expressed in MEFs (**E**) or *3d* iMac cells (**F**) were analyzed for the presence of EndoH-resistant glycans. Lysates were separated by SDS-PAGE and immunoblotted with the indicated antibodies. EndoH-sensitive (white arrow) and EndoH-resistant (black arrow) forms are indicated. (**G**) Mutation of UNC93B1 glycosylation sites abolishes EndoH resistant forms. Lysates from HEK293Ts transiently transfected with FLAG tagged UNC93B1-WT, -N251A or -N251A/N272A were separated by SDS-PAGE and immunoblotted with anti-FLAG antibody. (**H**) UNC93B1 is loaded into COPII vesicles. Digitonin-permeabilized COS7 cells expressing 3× FLAG-tagged UNC93B1-WT or UNC93B1-H412R, or no cells (Ø) were incubated with ATP regenerating system, GTP, and rat liver cytosol, as indicated, in an in vitro COPII budding assay. Vesicles purified by ultracentrifugation were analyzed by SDS-PAGE and immunoblot using the indicated antibodies. 20% of the COS7 cells prior to the budding reaction serves as a loading control (20% donor). ERGIC/p58 serves as a positive control for the formation of COPII vesicles. Results are representative of at least three experiments (**A**--**G**) or two experiments (**H**).**DOI:** [http://dx.doi.org/10.7554/eLife.00291.003](10.7554/eLife.00291.003)

UNC93B1 facilitates TLR9 loading into COPII vesicles {#s2-2}
----------------------------------------------------

Our previous work reported that three species of TLR9 can be detected within macrophages, representing distinct maturation stages: an initial 150-kDa species with EndoH-sensitive glycans corresponding to the ER-resident protein (TLR9-ER), a larger species with EndoH-resistant glycans corresponding to full-length receptor that has passed through the Golgi (TLR9-Precursor), and a 80-kDa band with EndoH-resistant glycans corresponding to the mature, cleaved receptor within endolysosomes (TLR9-Cleaved) ([Figure 2A](#fig2){ref-type="fig"}, lane 1) ([@bib22], [@bib21]). To examine how UNC93B1 function impacts TLR9 localization, we compared these three forms of TLR9 in immortalized macrophages derived from *Unc93b1*^3d/3d^ mice and complemented with UNC93B1-WT or UNC93B1-H412R. While all three bands were present in macrophages with functional UNC93B1, only the ER-resident form was detectable in cells expressing the UNC93B1-H412R mutant ([Figure 2A](#fig2){ref-type="fig"}), consistent with our previous analysis of TLR9 in UNC93B1 shRNA knockdown cells ([@bib22]). These data indicate that TLR9 does not reach the medial Golgi in the absence of functional UNC93B1. Because a pool of UNC93B1 can traffic from ER to Golgi by entering COPII vesicles ([Figure 1B](#fig1){ref-type="fig"}), we considered whether UNC93B1 regulates this aspect of TLR9 trafficking. Indeed, analysis of TLR9 loading into COPII vesicles revealed that TLR9 was only detectable in the presence of functional UNC93B1 whereas a control traffic protein, ERGIC/p58, was packaged independently of UNC93B1 ([Figure 2B](#fig2){ref-type="fig"}).10.7554/eLife.00291.004Figure 2.UNC93B1 controls ER exit of TLRs 3, 7, 9, 11, and 13.(**A**) TLR9 fails to exit the ER in cells lacking functional UNC93B1. Lysates from *3d* iMac cells complemented with either UNC93B1-WT or UNC93B1-H412R and expressing TLR9-HA were analyzed by SDS-PAGE and immunoblotted with the indicated antibodies. The precursor (black arrow), ER (white arrow) and cleaved (grey arrow) forms of TLR9-HA are indicated. (**B**) UNC93B1 is required for TLR9 loading into COPII vesicles. RAW264 macrophages stably transduced with retroviruses encoding control or Unc93b1-directed shRNA and expressing TLR9-HA were used in an in vitro COPII budding assay as described in ([Figure 1H](#fig1){ref-type="fig"}). Lysates of purified vesicles or donor membranes were probed with the indicated antibodies. (**C**) The transmembrane and cytosolic domain of TLR9 is sufficient to confer UNC93B1-dependence. (Left) schematic of TLR9 and the CD4-TLR9 chimera. Transmembrane (TM), ectodomain (Ecto) and cytosolic domain (Cyto) are indicated. (Right) CD4-TLR9 was expressed in HEK293Ts together with FLAG-tagged UNC93B1-WT or UNC93B1-H412R. Total lysates were analyzed by SDS-PAGE and immunoblotted with anti-CD4 and anti-FLAG antibodies. EndoH-sensitive (white arrow) and resistant (black arrow) forms are indicated. (**D**) CD4 trafficking to the cell surface is normal in *Unc93b1*^3d/3d^ cells. Splenocytes from C57BL/6 (blue line) or *Unc93b1*^3d/3d^ (red line) mice were stained with anti-CD4 and analyzed by flow cytometry. (**E**) CD4-TLR chimeric proteins for each of the indicated TLRs were expressed in HEK293Ts together with FLAG-tagged UNC93B1-WT or UNC93B1-H412R. Lysates were separated by SDS-PAGE and visualized by immunoblot with anti-HA and anti-FLAG antibodies. EndoH-sensitive (white arrows) and resistant (black arrows) forms are indicated. The chimeras were constructed as shown in [Figure 1E](#fig1){ref-type="fig"}, except with the addition of a C-terminal HA tag. Results are representative of at least three experiments (**A**, **C**, and **E**) or two experiments (**B** and **D**).**DOI:** [http://dx.doi.org/10.7554/eLife.00291.004](10.7554/eLife.00291.004)

Quality control mechanisms ensure that only properly folded proteins can exit the ER, and one mechanism by which UNC93B1 could regulate ER exit of TLR9 is through regulation of TLR9 folding, as has been reported for gp96 ([@bib63]). To address whether UNC93B1 serves as a folding chaperone, we tested whether a chimeric CD4-TLR9 protein, consisting of the ectodomain of CD4 fused to the transmembrane and cytosolic regions of TLR9 ([Figure 2C](#fig2){ref-type="fig"}, left), required UNC93B1 function. Because trafficking of CD4 is not UNC93B1-dependent ([Figure 2D](#fig2){ref-type="fig"}), this chimera can be used to test whether TLR9 requires UNC93B1 to ensure correct folding of the TLR9 ectodomain. CD4-TLR9 acquired EndoH-resistant glycans when expressed with UNC93B1-WT but not when expressed with mutant UNC93B1-H412R ([Figure 2C](#fig2){ref-type="fig"}, right). Thus, the requirement for UNC93B1 is not based on TLR9 ectodomain folding. Furthermore, the transmembrane domain and cytosolic regions of TLR9 are sufficient to mediate UNC93B1-dependent trafficking.

Taken together, these data indicate that UNC93B1 regulates ER to Golgi transport of TLR9. While we cannot rule out that a pool of UNC93B1 bypasses the Golgi en route to endosomes as suggested by others ([@bib11]; [@bib32]), this route does not seem relevant for UNC93B1-dependent TLR9 trafficking. Instead, UNC93B1 appears to control TLR9 entry into COPII vesicles.

UNC93B1 is required for proper trafficking of TLR3, TLR7, TLR9, TLR11, and TLR13 from the ER {#s2-3}
--------------------------------------------------------------------------------------------

We next sought to determine whether the dependence on UNC93B1 for ER exit is a general property of endosomal TLRs. We generated a panel of CD4-TLR fusion proteins and tested whether they required UNC93B1 to exit the ER, based on acquisition of EndoH-resistant glycans. As expected, ER exit of both CD4-TLR3 and CD4-TLR7 required UNC93B1, which is consistent with defective TLR3 and TLR7 signaling in *Unc93b1*^3d/3d^ mice ([@bib59]), whereas CD4-TLR4 trafficked independently of UNC93B1 ([Figure 2E](#fig2){ref-type="fig"}). CD4-TLR11 and CD4-TLR13 also required UNC93B1 for ER exit ([Figure 2E](#fig2){ref-type="fig"}). Less is known about the localization or trafficking of these TLRs, although biochemical studies have suggested that these TLRs can associate with UNC93B1 ([@bib11]; [@bib40]; [@bib49]). Our results are the first to show that UNC93B1 regulates the trafficking of TLR11 and TLR13 by controlling ER exit. Altogether, our data indicate that the role for UNC93B1 in controlling ER exit extends to all known endosomal TLRs (TLR3, TLR7, TLR9) as well as TLR11 and TLR13.

Mutational analysis reveals distinct regions of UNC93B1 required for ER exit and post-Golgi trafficking of TLR9 {#s2-4}
---------------------------------------------------------------------------------------------------------------

To define regions within UNC93B1 necessary for ER export of TLRs, we generated a series of N-and C-terminal truncation mutants. Based on the predicted topology of UNC93B1 ([@bib11]), the N- and C-termini face the cytosol, so we reasoned that these regions would be most likely to interact with putative trafficking factors ([Figure 3A](#fig3){ref-type="fig"}). Interestingly, N-terminal truncations resulted in a strong defect in TLR9 trafficking from the ER as evidenced by significantly reduced or absent precursor and cleaved forms of TLR9 in cells expressing the Δ50 and Δ57 UNC93B1 truncations ([Figure 3B](#fig3){ref-type="fig"}). This defective trafficking resulted in impaired responses to TLR9 ligands in macrophages, while TLR2 responses remained intact ([Figure 3C](#fig3){ref-type="fig"}). Taken together, our data indicate that the N-terminal region of UNC93B1 contains residues important for trafficking of TLR9 and UNC93B1 from the ER to endolysosomes. These findings are in agreement with a previous study showing that TLR9 responsiveness is strongly dependent on the N-terminus of UNC93B1, although this study did not directly examine TLR9 trafficking ([@bib24]). Furthermore, an UNC93B1 point mutant (D34A), which reduced TLR9 signaling but enhanced TLR7 signaling ([@bib24], [@bib23]), reduced TLR9 transport and cleavage ([Figure 3D](#fig3){ref-type="fig"}).10.7554/eLife.00291.005Figure 3.UNC93B1 mutants reveal two distinct roles in TLR9 trafficking.(**A**) Schematic of predicted UNC93B1 topology. UNC93B1 is a 12 pass transmembrane protein with terminal regions facing cytosol. Two putative N-linked glycosylation (N-Glyc) sites are indicated (top). Schematic of UNC93B1 (1--598 a.a.). The black numbered boxes represent predicted transmembrane domains, white boxes represent regions predicted to face the cytosol, and grey boxes represent regions predicted to face the lumen. Truncation and point mutations are indicated with arrows (bottom). (**B**) N- and C-terminal mutants of UNC93B1 have distinct TLR9 trafficking outcomes. Lysates from *3d* iMac cells expressing TLR9-HA and complemented with mutant forms of GFP-tagged UNC93B1 were subjected to SDS-PAGE and immunoblotted with anti-HA and anti-GFP antibodies. The precursor (black arrow), ER (white arrow) and cleaved (grey arrow) forms of TLR9-HA are indicated. n.s. indicates a non-specific band. (**C**) N- and C-terminal mutants of UNC93B1 have diminished TLR9 signaling. *3d* iMac cells complemented with WT or indicated mutant alleles of UNC93B1 were harvested for intracellular TNFα staining 5 hr after stimulation with 3 μM CpG, 1 μg/ml Pam3CSK4 or left unstimulated. Percentages of TNF-producing cells after gating on UNC93B1-GFP positive cells are plotted. (**D**) TLR9 trafficking to endolysosomes is impaired in UNC93B1-D34A cells. *3d* iMac cells were complemented with GFP-tagged UNC93B1-WT, -H412R or -D34A. Lysates were separated by SDS-PAGE and visualized by immunoblot with anti-HA and anti-GFP antibodies. The precursor (black arrow), ER (white arrow) and cleaved (grey arrow) forms of TLR9-HA are indicated. (**E**) UNC93B1 interacts with the cleaved form of TLR9. Immunoprecipitation of FLAG tagged UNC93B1 (WT or H412R) in *3d* iMac cells expressing TLR9-HA was performed in 1% digitonin with anti-FLAG matrix. UNC93B1 associated proteins were analyzed by SDS-PAGE and immunoblot with anti-FLAG and anti-HA antibodies. ER (white arrows) and cleaved (grey arrows) forms of TLR9-HA are indicated. All results are representative of at least three experiments.**DOI:** [http://dx.doi.org/10.7554/eLife.00291.005](10.7554/eLife.00291.005)

Our results thus far suggest that UNC93B1 controls the function of multiple TLRs by regulating their exit from the ER. However, UNC93B1 itself also exits the ER and is present in endolysosomes ([Figure 1A,H](#fig1){ref-type="fig"}). Moreover, we could detect both the precursor and cleaved forms of TLR9 associated with immunoprecipitated UNC93B1, suggesting that UNC93B1 and TLR9 remain associated after leaving the ER ([Figure 3E](#fig3){ref-type="fig"}). To test whether this post-ER interaction may have functional consequences, we screened UNC93B1 mutants for any role in TLR9 function beyond ER export. Strikingly, truncation of the UNC93B1 C-terminus (Δ523 and Δ538) resulted in an accumulation of the Golgi-modified precursor form of TLR9 and a marked reduction of the cleaved receptor ([Figure 3B](#fig3){ref-type="fig"}). This pattern suggests that TLR9 trafficking is blocked at some point after the medial Golgi, in contrast to the trafficking defect observed with N-terminal deletion mutants. Consistent with this interpretation, we observed reduced TLR9 signaling in cells expressing the Δ523 and Δ538 UNC93B1 mutants ([Figure 3C](#fig3){ref-type="fig"}). Thus, in addition to its role in ER export, UNC93B1 appears to regulate post-ER trafficking of TLR9.

UNC93B1 controls post-Golgi trafficking of TLR9 through recruitment of AP-2 {#s2-5}
---------------------------------------------------------------------------

We next sought to define the mechanism underlying the requirement for UNC93B1 in post-ER TLR9 trafficking. We focused on residues 539--542, YRYL, because they are evolutionarily conserved and fit the consensus for a YxxΦ motif (where Φ represents a hydrophobic residue), which may mediate protein interactions or serve as a site for phosphorylation ([@bib57]; [@bib46], [@bib45]; [@bib18]; [@bib10]) ([Figure 4A](#fig4){ref-type="fig"}). Mutation of Tyr539 to an Ala (Y539A) resulted in accumulation of the Golgi-modified precursor form of TLR9 and reduced TLR9 cleavage, similar to the block in TLR9 trafficking observed with the Δ538 truncation mutant ([Figure 4B](#fig4){ref-type="fig"}). Mutation of Leu-542 to Ala (L542A) and Tyr-539 to Phe (Y539F) gave similar results, although the block was not as complete as Y539A ([Figure 4C](#fig4){ref-type="fig"}). Responsiveness to TLR9 ligands was also reduced in UNC93B1-Y539A expressing cells, consistent with the block of TLR9 processing ([Figure 4D](#fig4){ref-type="fig"}).10.7554/eLife.00291.006Figure 4.UNC93B1 controls post-Golgi trafficking of TLR9 by recruiting AP-2.(**A**) Multi-species protein sequence alignment of residues in the UNC93B1 C-terminal tail. The YxxΦ motif, YRYL, is boxed. (**B**) Precursor TLR9 accumulates in UNC93B1-Y539A expressing cells. Lysates from *3d* iMac cells expressing TLR9-HA were complemented with the indicated GFP tagged UNC93B1, analyzed by SDS-PAGE, and immunoblotted with anti-HA and anti-GFP antibodies. The precursor (black arrow), ER (white arrow) and cleaved (grey arrow) forms of TLR9-HA are indicated. n.s. indicates a non-specific band. (**C**) Mutations of YxxΦ in UNC93B1 confer partial phenotypes in TLR9 trafficking when compared with Y539A. Lysates from *3d* iMac cells expressing TLR9-HA and GFP tagged UNC93B1-WT, H412R, Δ538, L542A, Y539F, Y539A were analyzed by SDS-PAGE and immunoblotted with anti-HA and anti-GFP antibodies. Presence of precursor (black arrow), ER (white arrow) and cleaved (grey arrow) forms of TLR9 are indicated. (**D**) TLR9 signaling is impaired in UNC93B1-Y539A cells. *3d* iMac cells, complemented with GFP tagged UNC93B1-WT, -H412R, or -Y539A, were harvested for intracellular TNFα staining 5 hr after stimulation with 3 μM CpG, 1 μg/ml Pam3CSK4 (Pam) or left unstimulated. Percentages of TNF-producing cells after gating on UNC93B1-GFP positive cells are plotted. (**E**) The C-terminal tail of UNC93B1 interacts with AP-2μ. Results from a yeast two-hybrid assay testing for interaction between the AP (-1A, -2, -3A, -4) µ subunits and the N- or C-terminal cytosolic regions of UNC93B1 (N- or C-tail UNC), are shown. Growth on --His--Trp--Leu plates (--His) or --Ade--Trp--Leu (--Ade) indicates interaction. Growth on --Trp--Leu plates (+His+Ade) serves as a control. (**F**)--(**G**) Tyr-539 on UNC93B1 mediates interaction with AP-2 complex. (**F**) Results from a yeast two-hybrid assay testing for interaction between the AP-2µ subunit and the C-terminal cytosolic region of UNC93B1 (UNC93B1 C-tail) from WT, the Y539A mutant, or the Δ538 mutant are shown. Growth on --His--Trp--Leu plates (--His) indicates interaction. Growth on --Trp--Leu plates (+His) serves as a control. (**G**) HEK293T were transiently transfected with AP-2µ-HA and FLAG tagged UNC93B1-WT, -Y539A. Cell lysates were incubated with anti-FLAG matrix, and UNC93B1-associated proteins were eluted with FLAG peptide, separated by SDS-PAGE and visualized by immunoblot with anti-HA or anti-FLAG antibodies. UNC93B1 associated AP-2µ is indicated with black arrow. Results are representative of at least three experiments (**B**, **D**--**F**) or two experiments (**C** and **G**).**DOI:** [http://dx.doi.org/10.7554/eLife.00291.006](10.7554/eLife.00291.006)

YxxΦ motifs can serve as binding sites for clathrin adaptor protein (AP) complexes, so we tested whether the C-terminal tail of UNC93B1 could interact with any of the four mammalian AP complexes. AP complexes consist of four subunits, of which the µ subunit typically determines cargo specificity ([@bib10]; [@bib44]). Because these interactions are often weak, we used a yeast two-hybrid (Y2H) assay in which the μ subunits of AP-1, AP-2, AP-3, and AP-4 were fused to the Gal4 activation domain and the UNC93B1 N- and C-terminal tails were fused to the Gal4 DNA binding domain. The C-terminal cytosolic region of UNC93B1 interacted strongly with AP-2μ, but not with the µ subunits of any of the other AP complexes ([Figure 4E](#fig4){ref-type="fig"}). Importantly, interaction with AP-2μ was abolished by the Δ538 truncation and the Y539A mutation ([Figure 4F](#fig4){ref-type="fig"}). Additionally, we were able to co-immunoprecipitate AP-2μ with UNC93B1-WT, but not with UNC93B1-Y539A ([Figure 4G](#fig4){ref-type="fig"}). Taken together, these data suggest that UNC93B1 directly recruits AP-2 via a YxxΦ motif present in its C-terminal cytosolic tail.

AP-2 complexes direct clathrin-mediated endocytosis of cargo from the plasma membrane. Therefore, our results suggest that UNC93B1 and TLR9 traffic together to the surface and require AP-2-mediated internalization to reach endocytic compartments. To test this possibility, we examined whether TLR9 required UNC93B1-mediated recruitment of AP-2 to gain access to endolysosomal compartments. Using immunofluorescence microscopy, we detected reduced colocalization of TLR9 and the lysosomal marker Lamp-1 in UNC93B1-Y539A-expressing cells ([Figure 5A](#fig5){ref-type="fig"}). We also compared surface expression of N-terminally tagged TLR9 in cells expressing different UNC93B1 alleles. While surface TLR9 was only weakly detectable in cells expressing UNC93B1-WT, expression of UNC93B1-Y539A increased the levels of FLAG-TLR9 at the cell surface ([Figure 5B](#fig5){ref-type="fig"}). Furthermore, as we found for TLR9-HA, the FLAG-TLR9 Golgi-modified precursor form accumulated in UNC93B1-Y539A expressing cells ([Figure 5C](#fig5){ref-type="fig"}). This result suggests that disruption of the interaction between UNC93B1 and AP-2 leads to defective endocytosis of TLR9 from the cell surface. In support of this model, siRNA knockdown of AP-2µ1 resulted in a similar increase in surface expression of TLR9 ([Figure 5D](#fig5){ref-type="fig"}) and accumulation of the TLR9 precursor form ([Figure 5E](#fig5){ref-type="fig"}). As a positive control for AP-2µ1 knockdown, we observed accumulation of CD71 (transferrin receptor) at the cell surface ([Figure 5D](#fig5){ref-type="fig"}). Taken together, these data support a model in which UNC93B1 interacts with AP-2 to traffic TLR9 from the cell surface to endolysosomes.10.7554/eLife.00291.007Figure 5.Failure to recruit AP-2 by UNC93B1 results in cell surface accumulation of TLR9.(**A**) TLR9 fails to traffic to endolysosomes in UNC93B1-Y539A expressing cells. Localization of TLR9-HA and Lamp-1 in *3d* iMac cells complemented with UNC93B1-WT, -H412R, or -Y539A was determined by immunofluorescence microscopy. Representative images of Lamp-1 (left), TLR9 (middle), and a pseudo-colored merged image for each UNC93B1 allele are shown. Arrowheads indicate areas of Lamp-1/TLR9 colocalization. (**B**) TLR9 accumulates at the cell surface in UNC93B1-Y539A expressing cells. HEK293Ts transfected with N-terminally tagged 3× FLAG-TLR9 and the indicated UNC93B1 alleles were stained with anti-FLAG and goat anti-mouse IgG secondary antibodies. FLAG staining was measured by flow cytometry. (**C**) The TLR9 precursor form accumulates in HEK293Ts expressing N-terminally tagged FLAG-TLR9 and UNC93B1-Y539A. Lysates from HEK293Ts stably expressing N-terminally tagged 3× FLAG TLR9 and GFP tagged UNC93B1-WT, -H412R, or -Y539A were harvested, treated with EndoH, separated by SDS-PAGE, and visualized by immunoblot with anti-FLAG and anti-GFP antibodies. (**D**) TLR9 accumulates at the cell surface in cells lacking AP-2. HEK293Ts stably expressing 3× FLAG-TLR9 with or without WT UNC93B1 were treated with AP-2μ (AP2M1) or control siRNA for 96 hr. FLAG staining was measured on intact (surface) or permeabilized (Perm) cells as described in (**G**). Anti-CD71 (transferrin receptor) staining serves as a control for AP-2 knockdown. (**E**) Absence of AP-2 causes accumulation of TLR9 precursor form. HEK293Ts were treated with control or AP-2µ siRNA. After 48 hr, siRNA treated cells were transiently transfected with TLR9-HA and GFP tagged UNC93B1-WT. Lysates were harvested 24 hr later for EndoH assay as described in (**A**). The TLR9 precursor form (black arrow) is indicated in each panel. Results are representative of at least three experiments (**B** and **D**) Or two (**A**, **C**, and **E**).**DOI:** [http://dx.doi.org/10.7554/eLife.00291.007](10.7554/eLife.00291.007)

UNC93B1 differentially controls TLR7 and TLR9 {#s2-6}
---------------------------------------------

Having established the mechanisms by which UNC93B1 facilitates TLR9 delivery to endolysosomes, we next examined whether TLR7 is under similar regulation. However, for reasons that remain unclear, detection of endogenous or epitope-tagged exogenous TLR7 protein is quite challenging. Consequently, the evidence that TLR7 undergoes ectodomain processing is limited ([@bib21]), and one group has reported that TLR7 is not cleaved ([@bib48]). We synthesized a TLR7 coding sequence optimized for efficient translation (see 'Materials and methods') and found that our ability to detect TLR7 protein was significantly improved. Cleaved TLR7 was detected in macrophages expressing UNC93B1-WT but not in macrophages expressing UNC93B1-H412R ([Figure 6A](#fig6){ref-type="fig"}). Both the full-length and cleaved forms of TLR7 possessed EndoH-resistant glycans, although fewer of the TLR7 N-linked glycans acquired these modifications than for TLR9 ([Figure 6B](#fig6){ref-type="fig"}, top). These results confirm our previous findings that TLR7 undergoes ectodomain proteolysis and traffics through the Golgi en route to endolysosomes. Importantly, our results confirm that TLR7 trafficking is dependent on UNC93B1.10.7554/eLife.00291.008Figure 6.Differential trafficking of TLR7 and TLR9.(**A**) TLR7 trafficking can be monitored biochemically and is UNC93B1-dependent. Lysates from *3d* iMac cells expressing TLR7-HA and complemented with GFP-tagged UNC93B1-WT, -H412R or -Y539A were separated by SDS-PAGE and immunoblotted with anti-HA and anti-GFP antibodies. ER (white arrows) and cleaved (grey arrows) forms of TLR7-HA are indicated. (**B**) TLR7 acquires EndoH resistance. TLR7-HA was immunoprecipitated from *3d* iMac cells expressing UNC93B1-WT, -H412R, or -Y539A, treated with EndoH (E), PNGaseF (P) or left untreated (−), and visualized by anti-HA immunoblot. Asterisk indicates precursor form of the receptor. The bracket indicates the migration difference between EndoH-treated and PNGaseF-treated TLR7. (**C**) UNC93B1 interacts with ER and cleaved forms of TLR7. GFP-tagged UNC93B1-WT or -H412R were immunoprecipitated from *3d* iMac cells expressing TLR7-HA. UNC93B1 associated proteins were analyzed by SDS-PAGE and immunoblotted with anti-HA and anti-GFP antibodies. ER (white arrows) and cleaved (grey arrows) forms of TLR7-HA are indicated. (**D**) TLR7 signaling is normal in UNC93B1-Y539A cells. *3d* iMac cells complemented with GFP tagged UNC93B1-WT, -H412R, or -Y539A were stimulated with 100 to 25 ng/ml R848 for 5 hr and intracellular TNFα stain was performed. Percentages of TNF-producing cells after gating on UNC93B1-GFP positive cells are plotted. (**E**) TLR7 interacts with AP-4μ. Results from a yeast two-hybrid assay testing for interaction between the AP-1, AP-2, AP-3, and AP-4 µ subunits and the C-terminal cytosolic region of TLR7. Growth on --His--Trp--Leu plates (--His) indicates interaction. Growth on --Trp--Leu plates (+His) serves as a control. (**F**) TLR7-Y892A is unable to interact with AP-4μ. Results from a yeast two-hybrid assay testing for interaction between the AP-4μ and TLR7 YxxΦ mutants (Y882A, Y892A, or double). Conditions are as described in (**E**). (**G**) TLR7-Y892A does not respond to TLR7 ligands. HEK293T cells were transiently transfected with an NF-κB luciferase reporter as well as expression plasmids encoding TLR7, TLR7-Y892A, or empty vector. Luciferase production was assayed 16 hr after stimulation with 10 µg/ml R848. (**H**) TLR7-Y892A trafficking is impaired. TLR7^−/−^ bone marrow derived macrophages (BMMs) were transduced with HA-tagged TLR7-WT or TLR7-Y892A. Cell lysates were analyzed by SDS-PAGE and immunoblotted with anti-HA antibodies. ER (white arrows) and cleaved (grey arrows) forms of TLR7-HA are indicated. Results are representative of at least three experiments (**A**, **D**, and **E**) or two experiments (**B**, **C**, and **F**--**H**).**DOI:** [http://dx.doi.org/10.7554/eLife.00291.008](10.7554/eLife.00291.008)

We next examined whether UNC93B1 controls post-Golgi sorting of TLR7 as it does for TLR9. Similar to TLR9, both the full-length and cleaved forms of TLR7 associated with UNC93B1 suggesting that UNC93B1 traffics with TLR7 to endolysosomes ([Figure 6C](#fig6){ref-type="fig"}). However, unlike TLR9, the response to TLR7 ligands was normal in UNC93B1-Y539A expressing cells ([Figure 6D](#fig6){ref-type="fig"}). Moreover, the amount of cleaved TLR7 was unaffected, and the TLR7 Golgi-modified precursor form did not accumulate in these cells ([Figure 6A,B](#fig6){ref-type="fig"}). Thus, delivery of TLR7 to endolysosomes appears to be independent of the UNC93B1/AP-2 pathway.

If TLR7 does not require the UNC93B1-mediated recruitment of AP-2 for proper trafficking, then how does the receptor reach endolysosomes? We considered the possibility that TLR7 may recruit AP-2 directly, thereby obviating the need for UNC93B1. However, when we screened by Y2H for interactions between the cytosolic region of TLR7 and AP-1, AP-2, AP-3, and AP-4, we found that TLR7 interacted specifically with AP-4μ but not AP-2μ ([Figure 6E](#fig6){ref-type="fig"}). We identified three potential YxxΦ motifs within TLR7, and mutating one of these (Tyr-892) disrupted the interaction with AP-4 ([Figure 6F](#fig6){ref-type="fig"}). In addition, a TLR7-Y892A mutant no longer responded to TLR7 ligands ([Figure 6G](#fig6){ref-type="fig"}) and displayed reduced ectodomain processing when expressed in bone marrow derived macrophages, suggesting that AP-4 is required for TLR7 delivery to endosomes ([Figure 6H](#fig6){ref-type="fig"}). AP-4 has been implicated in vesicular trafficking between the trans Golgi network (TGN) and endosomes ([@bib20]; [@bib1]; [@bib56]; [@bib5]; [@bib12]). Therefore, the association between AP-4 and TLR7 suggests that TLR7 is diverted from the secretory pathway at the TGN and delivered directly to endosomes while continually associating with UNC93B1. Thus, the mechanisms controlling trafficking of TLR7 and TLR9 to the compartments from which they signal are distinct.

Several UNC93B1 dependent TLRs traffic independently of the UNC93B1/AP-2 pathway {#s2-7}
--------------------------------------------------------------------------------

We next sought to determine whether the post-Golgi trafficking of other UNC93B1-dependent TLRs is similar to either of the pathways we have described for TLR7 and TLR9. First, we tested whether TLR3, TLR11, and TLR13 responses were affected in UNC93B1-Y539A expressing cells. Unfortunately, both wildtype and UNC93B1-Y539A cells were unresponsive to Poly I:C, profilin, and flagellin (data not shown), so we could not evaluate TLR3 or TLR11 signaling ([@bib2]; [@bib64]; [@bib38]). However, cells expressing wildtype UNC93B1 responded robustly to the oligoribonucleotide sequence derived from *Staphylococcus aureus* (hereafter referred to as Sa ORN) that was recently shown to stimulate TLR13 ([@bib36]; [@bib47]). The response of UNC93B1-Y539A cells stimulated with Sa ORN was comparable to that of wildtype cells, suggesting that TLR13 does not require the UNC93B1/AP-2 pathway to access endosomal signaling compartments ([Figure 7A](#fig7){ref-type="fig"}).10.7554/eLife.00291.009Figure 7.TLR11, TLR12, and TLR13 traffic independently of the UNC93B1/AP-2 pathway.(**A**) TLR13 signaling is unaffected by UNC93B1-Y539A. *3d* iMac cells expressing UNC93B1-WT, -H412R, or -Y539A were stimulated with 1 μg/ml Pam3CSK4 (black) or 1 nM Sa ORN complexed with DOTAP (grey) and harvested for intracellular TNFα staining 5 hr after stimulation. Percentages of TNF-producing cells are plotted. (**B**) TLR13 trafficking is unaffected by UNC93B1-Y539A. TLR13-HA was immunoprecipitated from *3d* iMac cells expressing UNC93B1-WT, -H412R, or -Y539A, treated with EndoH (E), PNGaseF (P) or left untreated (N), and visualized by anti-HA immunoblot. Asterisk indicates full length EndoH resistant form of the receptor. (**C**) and (**D**) TLR11 (**C**) and TLR12 (**D**) trafficking is unaffected by UNC93B1-Y539A. TLR11 and TLR12 was treated as in (**B**). Asterisk indicates full length EndoH resistant form of the receptor. The bracket indicates the migration difference between EndoH-treated and PNGaseF-treated cleaved form of the receptors. Results are representative of at least three experiments (**A**) or two experiments (**B**--**D**).**DOI:** [http://dx.doi.org/10.7554/eLife.00291.009](10.7554/eLife.00291.009)

We also examined trafficking of other UNC93B1-dependent TLRs biochemically in cells expressing UNC93B1-WT, UNC93B1-H412R, or UNC93B1-Y539A. TLR13 acquired EndoH-resistant glycans, and the glycosylation was absent in UNC93B1-H412R cells but unaffected in UNC93B1-Y539A expressing cells. Moreover, the full-length EndoH-resistant form did not accumulate in these cells, as we observed for TLR9. Together with the responses to TLR13 ligands, these results indicate that TLR13 traffics independently of the UNC93B1/AP-2 pathway. We performed similar experiments with TLR11 and TLR12, which both recognize profilin ([@bib64]; [@bib33]). Both of these receptors appear to undergo ectodomain cleavage, although the sizes of the cleaved receptors are quite distinct: ∼45 kDa for TLR11 and ∼75 kDa for TLR12 ([Figure 7C,D](#fig7){ref-type="fig"}). Importantly, both receptors acquired EndoH-resistant glycans, and the glycosylation was unaffected in UNC93B1-Y539A expressing cells. Thus, TLR11 and TLR12 also do not require the UNC93B1/AP-2 pathway for proper trafficking.

Altogether, these results suggest that TLR9 trafficking may be unusual among the endosomal TLRs by trafficking via the plasma membrane en route to endosomes. It is important to note, though, that we have not examined TLR3 trafficking. Thus, it remains possible that TLR3 may also utilize this route, especially considering the several reports that describe TLR3 surface expression ([@bib52], [@bib53]; [@bib51]; [@bib62]).

TLR7 and TLR9 association with UNC93B1 is mutually exclusive {#s2-8}
------------------------------------------------------------

We have shown that UNC93B1 associates with both the full-length and cleaved forms of TLR9 and TLR7 ([Figures 3E, 6C](#fig3 fig6){ref-type="fig"}); however, the differential post-Golgi trafficking routes taken by TLR7 and TLR9 suggest that UNC93B1 must associate with TLR7 and TLR9 in separate complexes. To test this possibility directly, we examined interactions between TLR7, TLR9, and UNC93B1 by immunoprecipitation. While both TLR7 and TLR9 could precipitate UNC93B1, we could never detect interactions between the two receptors ([Figure 8](#fig8){ref-type="fig"}). Thus, UNC93B1 binding to TLR7 appears to preclude binding to TLR9 and vice versa. These data support the idea that endosomal TLRs compete for binding to UNC93B1 in order to exit from the ER ([@bib61]; [@bib24], [@bib23]).10.7554/eLife.00291.010Figure 8.TLR7 and TLR9 association with UNC93B1 is mutually exclusive.TLR9 and TLR7 associate with UNC93B1 in distinct complexes. *3d* iMac cells expressing TLR9-HA, TLR7-V5-His, and WT UNC93B1-GFP (WT) or no UNC93B1 (−) were lysed in TNT buffer conditions then incubated with anti-HA matrix or anti-V5 protein A/G beads. Immunoprecipitated proteins were analyzed by SDS-PAGE and immunoblotted with HA, GFP and V5 antibodies. Asterisk indicates remaining UNC93B1-GFP signal. Results are representative of two experiments.**DOI:** [http://dx.doi.org/10.7554/eLife.00291.010](10.7554/eLife.00291.010)

Discussion {#s3}
==========

The studies presented here address several poorly understood aspects of TLR cell biology. First, we describe mechanisms by which UNC93B1 can regulate multiple aspects of TLR trafficking. UNC93B1 controls exit of at least six TLRs (TLR3, TLR7, TLR9, TLR11, TLR12 and TLR13) from the ER by regulating their loading into COPII vesicles. In addition, we show that UNC93B1 acts at the cell surface by recruiting clathrin AP-2 to internalize TLR9 from the plasma membrane into endosomes. Perhaps most surprisingly, our results indicate that TLR7 and TLR9 have different requirements for UNC93B1 and demonstrate that the localization of these receptors is controlled through distinct post-Golgi trafficking mechanisms. This last point may provide an explanation for the contrasting roles played by TLR7 and TLR9 in SLE.

Previous work has demonstrated that TLR9 and TLR7 fail to reach endosomes in the absence of functional UNC93B1 ([@bib32]). Interactions between UNC93B1 and TLRs appear necessary for proper trafficking ([@bib11]), but until our work it was unclear how UNC93B1 mediated delivery of TLRs to endosomal compartments. The most direct examination of UNC93B1 function concluded that the protein translocates with TLRs from the ER to endolysosomes without passing through the Golgi apparatus ([@bib11]; [@bib32]). In contrast, we propose that UNC93B1 is required for loading of TLR9 into COPII vesicles, which direct transport from the ER to the cis-Golgi ([@bib65]). Multiple lines of evidence support the conclusion that UNC93B1 regulates this essential aspect of ER exit. First, UNC93B1 is detected within COPII vesicles, but the nonfunctional UNC93B1-H412R mutant is not. Second, a fraction of UNC93B1 protein acquires EndoH-resistant glycans, indicative of trafficking through the medial-Golgi. Again, the UNC93B1-H412R mutant does not acquire EndoH resistance. Third, in cells lacking UNC93B1, TLR9 is not detected within COPII vesicles. Fourth, the EndoH-resistant precursor and cleaved forms of TLR9 are absent in cells not expressing functional UNC93B1. Importantly, we ruled out the possibility that UNC93B1 functions as a folding chaperone by showing that CD4-TLR fusion proteins require UNC93B1 for ER exit. Altogether, these results argue that UNC93B1 regulates TLR passage through the general secretory pathway, instead of controlling direct translocation between the ER and endosomes. We cannot formally rule out that a pool of UNC93B1 uses this non-canonical route, but it would seem to have little if any relevance for TLR trafficking. The recent identification of Sec22b as a factor required for ER to endosome translocation may allow for further investigation of this possibility ([@bib14]).

Our work suggests that at least six, and possibly seven, TLRs are regulated by UNC93B1 in mice. TLR3, TLR7, TLR9, TLR11, TLR12 and TLR13 require UNC93B1 for exit from the ER. It is likely that TLR8 also requires UNC93B1 ([@bib28]), based on its similarity to TLR7, but we have not yet tested this possibility. Regulation of ER exit of TLR11, TLR12 and TLR13 by UNC93B1 is not completely unexpected, as these TLRs were previously linked to UNC93B1 ([@bib11]; [@bib40]; [@bib49]; [@bib33]; [@bib47]). The determinants of UNC93B1 binding to each of these TLRs remain poorly defined. Residues within the first 50 amino acids of UNC93B1 appear necessary for export of TLR9 but not for export of TLR7. This result suggests that distinct regions of UNC93B1 are required for association with TLR9 and TLR7, although measuring how these mutations impact TLR/UNC93B1 interactions has been challenging for us and for other groups ([@bib24]). The fact that UNC93B1-D34A-expressing mice exhibit enhanced TLR7 responses and develop SLE suggests that UNC93B1 is limiting in the ER, at least for TLR7 ([@bib23]). Presumably, the inability of UNC93B1-D34A to interact with TLR9 results in greater TLR7 export and enhanced signaling. These results and our finding that TLR7 and TLR9 association with UNC93B1 is mutually exclusive suggest that each UNC93B1 molecule may interact with a single TLR. This specificity is particularly important in light of our findings that trafficking routes of TLR7 and TLR9 are distinct. Whether UNC93B1 is similarly selective for other TLRs and identification of the domains that mediate any selectivity are important topics for future studies. Selective export of individual TLRs may provide a mechanism for differential regulation of endosomal TLR responses between cell types or in response to external signals.

Through analysis of UNC93B1 mutants we identified an additional role for UNC93B1 in directing post-Golgi trafficking of TLR9. Unlike typical COPII loading factors, UNC93B1 remains associated with its cargo, traffics with TLR9 to the cell surface, and associates with AP-2 via a YXXΦ motif ([Figure 9](#fig9){ref-type="fig"}). Recruitment of AP-2 is necessary for internalization of TLR9 and subsequent trafficking to endolysosomes. This AP-2-dependent trafficking route has been described for several proteins localized to endolysosomes, including LAMP-1, LAMP-2, and MHC Class II ([@bib26]; [@bib29]; [@bib39]). In some cases, the same protein can access endocytic compartments through multiple routes. For example, LAMP-1/2 can also traffic directly from the TGN to endosomes ([@bib30]). While we cannot rule out that TLR9 may reach endolysosomes through multiple routes, AP-2-mediated internalization appears to be the main pathway of delivery, at least in the cells types we have examined. It is interesting that TLR9 and UNC93B1 would have evolved such dependency on this route, especially considering the potential for self-DNA recognition associated with surface localization of TLR9 ([@bib7]; [@bib42]). Indeed, our results appear to underscore why the requirement for ectodomain processing is a critical mechanism ensuring that receptors at the plasma membrane remain nonfunctional ([@bib22]; [@bib42]).10.7554/eLife.00291.011Figure 9.Trafficking pathways controlling localization of endosomal TLRs.UNC93B1 interacts with several TLRs in the ER and facilitates loading into COPII vesicles. Unlike typical COPII loading factors, UNC93B1 remains associated with TLR9 and TLR7 after exit from the ER. Through its recruitment of AP-2, UNC93B1 is necessary for endocytosis of TLR9 from the plasma membrane into endosomes. TLR7 does not rely on this trafficking route. Instead, TLR7 utilizes AP-4 to bypass the cell surface and traffic directly to endosomes. This difference in trafficking may result in TLR9 and TLR7 accessing distinct compartments with unique functional properties related to the function of each receptor.**DOI:** [http://dx.doi.org/10.7554/eLife.00291.011](10.7554/eLife.00291.011)

One of the most exciting aspects of our study is the observation that trafficking of TLR7 and TLR9 are distinct. We find no evidence that TLR7 requires UNC93B1 for recruitment of AP-2. Instead, TLR7 appears to employ AP-4 in a direct route of traffic from the TGN to the endosome. These results provide the first evidence that different pathways control TLR7 and TLR9 trafficking and localization. One potential implication of this result is that these pathways may deliver TLR9 and TLR7 to distinct compartments with different access to ligands or distinct signaling properties. We find that TLR11, TLR12 and TLR13, like TLR7, do not require the UNC93B1/AP-2 pathway. However, it remains to be determined whether these TLRs utilize the AP-4 pathway or another pathway to traffic from TGN to endosomes. Further compartmental specialization is generated by AP-3, which interacts with TLR9 and directs the receptor to endosomal compartments dedicated to type I interferon signaling ([@bib27]; [@bib9]; [@bib54]). TLR7 may also utilize AP-3 to reach this specialized compartment, although we could not detect interaction between AP-3 and TLR7 ([Figure 6E](#fig6){ref-type="fig"}). Whether there is transport of TLRs between each of the compartments serviced by AP-2, AP-3, and AP-4 remains an open question.

The use of distinct molecular pathways to regulate endosomal TLRs may allow for differential regulation of trafficking, either in response to external cues or between different cell types. In addition, TLR7- and TLR9-containing compartments may have differing abilities to access internalized ligands, influencing responses to microbial or self ligands. These possibilities are particularly intriguing when considering the contrasting roles played by TLR7 and TLR9 in SLE, where loss of TLR7 protects against disease while loss of TLR9 exacerbates disease ([@bib17]). Our findings raise the possibility that distinct cell biological regulation may underlie the different roles played by these receptors in autoimmune disease. Defining the mechanisms underlying this regulation may help explain the etiology of certain autoimmune diseases as well as provide opportunities to selectively manipulate distinct aspects of TLR activation.

Materials and methods {#s4}
=====================

Antibodies and reagents {#s4-1}
-----------------------

The following antibodies were used for immunoblots, immunoprecipitations, or flow cytometry: anti-HA as purified antibody or matrix (3F10; Roche, Indianapolis, IN), anti-FLAG as purified antibody or matrix (M2 and M5; Sigma-Aldrich, St. Louis, MO), anti-GFP (JL-8; Clontech Laboratories, Inc, Mountain View, CA), anti-GFP as purified or matrix (RQ2; MBL International Corporation, Woburn, MA), anti-*myc* (purified mouse; Invitrogen, Grand Island, NY), anti-V5 (mouse monoclonal; Invitrogen) anti-CD4 (RM4-5; BD Biosciences, San Jose, CA), anti-Lamp-1 (1D4B; BD Biosciences), anti-calnexin (rabbit polyclonal; Enzo Life Sciences, Farmingdale, NY), anti-ERGIC/p58 (rabbit) has been previously described ([@bib41]), anti-TNFα-PE or -APC (MP6-XT22; eBiosciences, San Diego, CA), anti-CD71-APC (OKT9; eBiosciences), goat anti-mouse IgG-AlexaFluor647 (Invitrogen), goat anti-rat-HRP, sheep anti-mouse-HRP, and donkey anti-rabbit-HRP (GE Healthcare, Waukesha, WI). For immunofluorescence: rabbit anti-HA (Y11; Santa Cruz Biotechnology, Dallas, TX), goat anti-mouse Cy3 (Jackson Immunoresearch, West Grove, PA), goat anti-rabbit-AlexaFluor647 (Invitrogen). The following TLR ligands were used to stimulate cells: CpG ODN (TCCATGACGTTCCTGACGTT, all phosphorothioate linkages) and Sa ORN ('Sa17'; [@bib47]) (GACGGAAAGACCCCGUG RNA sequence purchased from Integrated DNA Technologies, San Diego, CA), R848 (InvivoGen, San Diego, CA), and Pam3CSK4 (InvivoGen). 3× FLAG peptide was purchased from Sigma-Aldrich. Digitonin was purchased from Wako Pure Chemical Industries, Ltd. (Richmond, VA) or Calbiochem (Billerica, MA). Lipofectamine-LTX reagent (Invitrogen) was used for transient transfection of plasmid DNA. Lipofectamine RNAiMAX reagent (Invitrogen) was used for siRNA delivery. DOTAP liposomal transfection reagent (Roche) was used for transfection of Sa ORN in PBS. OptiMEM-I (Invitrogen) was used as media to form nucleic acid complexes for transient transfections.

Mice {#s4-2}
----

*Unc93b1*^3d/3d^ mice ([@bib59]) were obtained from the MMRRC at University of California, Davis. C57Bl/6 were purchased from The Jackson Laboratory (Bar Harbor, ME). All mice were housed in the animal facilities at the University of California, Berkeley according to guidelines of the Institutional Animal Care and Use Committee.

Plasmid constructs {#s4-3}
------------------

Pfu Turbo polymerase (Agilent Technologies, Santa Clara, CA) was used according to manufacturer\'s instructions for site directed mutagenesis. The following mouse stem cell virus (MSCV)-based retroviral vectors were used to express UNC93B1, TLR9, and TLR7 in cell lines: MSCV2.2 (IRES-GFP), MSCV-Thy1.1 (IRES Thy1.1), MIGR2 (IRES-hCD2). The following epitope tags were fused to the C-terminus of UNC93B1: 3× FLAG (DYKDHDGDYKDHDIDYKDDDDK), Myc (EQKLISEEDL), HA (YPYDVPDYA) and entire eGFP cDNA derived from pIRES-eGFP plasmid (Clontech). TLR9 was fused to HA at the C-terminal end or with 3× FLAG at the N-terminal end as previously described ([@bib22]; [@bib42]). TLR7 sequence was synthesized after codon optimization by Invitrogen\'s GeneArt Gene Synthesis service and cloned into same vectors as TLR9 and tagged with C-terminal HA or C-terminal V5-His (GKPIPNPLLGLDST-HHHHHH). TLR11, TLR12, TLR13 was C-terminally tagged with HA and cloned into MSCV2.2. UNC93B1 shRNA and control were generated in MSCV-Lmp, as previously described ([@bib22]). CD4-TLR chimeras were generated in pCDNA3.1 (Invitrogen). CD4 extracellular domain (mouse 1--390 a.a.) was fused to transmembrane domain and cytosolic regions of the following TLRs and C-terminally tagged with HA: TLR4 (620--835 a.a.), TLR9 (mouse 803--1032 a.a.), TLR3 (human 691--904 a.a.), TLR7 (human 825--1049), TLR11 (mouse 703--926 a.a.), TLR13 (mouse 770--991 a.a.). Rat AP-2μ-HA containing an internal HA tag in pCDNA3 was provided by A. Sorkin (while at the University of California, San Diego, CA, now at the University of Pittsburgh, PA) ([@bib43]).

For yeast-two-hybrid assays, N-terminal (1--59 a.a.) and C-terminal (515--598 a.a.) cytosolic regions of UNC93B1 were fused to Gal4 DNA binding domain (DBD) by cloning into pGBT9 (Clontech). TLR7 cytosolic region (mouse 862--1061 a.a.), TLR9 cytosolic region (mouse 838--1032 a.a.), fused to Gal4-DBD by cloning into pGBT9. AP-1Aμ, AP-2μ, AP-3Aμ, AP-3Bμ, AP-4μ were cloned into pACT2 (Clontech) were provided by J. Bonifacino (National Institutes of Health, Bethesda, MD).

Cell lines and tissue culture conditions {#s4-4}
----------------------------------------

HEK293T cells were obtained from American Type Culture Collection (ATCC, Manassas, VA). GP2-293 packaging cell lines were obtained from Clontech. Phoenix-Eco (ØNX-E) cells were provided by G. Nolan (Stanford University, Palo Alto, CA). Mouse embryonic fibroblasts (MEFs) are TLR2/TLR4 double knockout genotype immortalized with SV40 large T-antigen. COS7 were obtained from the Berkeley cell culture facility. The above cell lines were cultured in DMEM supplemented with 10% (vol/vol) FCS, L-glutamine, penicillin-streptomycin, sodium pyruvate, and HEPES (pH 7.2) (Invitrogen). RAW264 macrophage cell lines (ATCC) and immortalized macrophages (generated as described below) were cultured in RPMI 1640 (same supplements as above).

To generate immortalized macrophage cell lines, bone marrow from *Unc93b1*^3d/3d^ mice was cultured in RPMI 1640 media supplemented with supernatant containing M-CSF, as previously described ([@bib3]), as well as virus encoding both v-raf and v-myc ([@bib8]). After 8 days, macrophages were removed from M-CSF-containing media and cultured in RPMI 1640 media with added supplements as described above.

Retroviral transduction {#s4-5}
-----------------------

For retroviral transduction of immortalized macrophages, VSV-G-psuedotyped retrovirus was made in GP2-293 packaging cells (Clontech). GP2-293 cells were transfected with retroviral vectors and pVSV-G using Lipofectamine LTX reagent. 24 hr post-transfection, cells were incubated at 32°C. 48 hr post-transfection viral supernatant (with polybrene at final 5 μg/ml) and was used to infect target cells overnight at 32°C and protein expression was checked 48 hr later. Target cells were sorted on MoFlo Beckman Coulter Sorter to match expression.

For retroviral transduction of bone marrow derived macrophages, retrovirus was produced with the ØNX-E packaging line. Bone marrow cells were transduced with viral supernatant on two successive days while cultured in M-CSF containing RPMI media until harvested on day 8.

Luciferase assays {#s4-6}
-----------------

Activation of NF-κB in HEK293T cells was performed as previously described ([@bib22]). Briefly, transfections were performed in OptiMEM-I (Invitrogen) with LTX transfection reagent (Invitrogen) according to manufacturer\'s guidelines. Cells were stimulated with 1--10 µg/ml R848 after 24 hr and lysed by passive lysis after an additional 12--16 hr. Luciferase activity was measured on a LMaxII-384 luminometer (Molecular Devices, Sunnyvale, CA).

Lysate preparation, SDS-PAGE, immunoblotting {#s4-7}
--------------------------------------------

Cell lysates were prepared with TNT buffer (20 mM Tris \[pH 8.0\], 200 mM NaCl, 1% Triton X-100, 4 mM EDTA and supplemented with EDTA-free complete protease inhibitor cocktail; Roche) unless otherwise noted. Digitonin lysis buffer (50 mM Tris \[pH 7.4\], 150 mM NaCl, 5 mM EDTA \[pH 8.0\], 1% Digitonin added fresh and supplemented with EDTA-free complete protease inhibitor cocktail) was used for co-immunoprecipitations. Lysates were cleared of insoluble material by centrifugation. For immunoprecipitations, lysates were incubated with anti-HA matrix, anti-FLAG matrix, anti-GFP matrix or with purified antibody conjugated to Protein A/G beads (ThermoFisher Pierce, Rockford, IL) and precipitated proteins were denatured in SDS-PAGE buffer separated by SDS-PAGE (Tris--HCl self cast gels or Bio-Rad TGX precast gels \[Bio-Rad, Hercules, CA\]), and probed by the indicated antibodies. For anti-FLAG matrix immunoprecipitations, 3× FLAG peptide (Sigma-Aldrich) was used to elute.

Endoglycosidase H assay {#s4-8}
-----------------------

Immunoprecpitated proteins or total lysate were denatured and treated with Endoglycosidase H or PNGase F according to manufacturer\'s instructions. All enzymes and buffers were purchased from New England Biolabs (Ipswich, MA).

Flow cytometry {#s4-9}
--------------

To measure TNFα production, we added brefeldinA to cells 30 min after stimulation, and cells were collected after an additional 4 hr, and cells were stained for intracellular cytokines with a Fixation & Permeabilization kit according to manufacturer\'s instructions (eBioscience).

For FLAG-TLR surface expression, HEK293T cells stably expressing N-terminally tagged 3× FLAG-TLR9 were stained with anti-FLAG (M5; Sigma-Aldrich) antibody followed by Alexa 647 goat anti-mouse IgG secondary antibody (Invitrogen). All data were collected on LSR II (Becton Dickinson, Franklin Lakes, NJ) or FC-500 (Beckman Coulter, Indianapolis, IN) flow cytometers and were analyzed with FloJo software (TreeStar, Inc. Ashland, OR).

Microscopy {#s4-10}
----------

Co-localization studies were performed on Leica TCS confocal microscope. The images were taken with a 40× oil immersion objective and treated with 2× digital zoom. All images were processed by Adobe Photoshop. Cells were allowed to settle overnight on coverslips. Coverslips were washed with PBS, fixed with 4% paraformaldehyde/PBS, and permeabilized with 0.5% saponin/PBS. Slides were incubated in freshly made 0.1% sodium borohydride 0.1% saponin before being stained in 1% Bovine Serum Albumin (Fisher Scientific, Pittsburgh, PA)/0.1% saponin in PBS with rabbit anti-HA (Santa Cruz), rat anti-Lamp-1 (BD Biosciences) then with secondary antibodies, goat anti-Rabbit 647 (Invitrogen) and goat anti-Rat Cy3 (Jackson Immunoresearch).

Phagosome isolation {#s4-11}
-------------------

RAW264 cells were used to isolate phagosomes as previously described ([@bib22]). Briefly, cells were incubated with 2 μM latex beads (Polysciences, Inc., Warrington, PA) for 1 hr. Cells were disrupted by dounce homogenization to release intact phagosomes. Following centrifugation in sucrose step gradient, phagosomes were harvested from the 20--10% sucrose interface. Lysates were analyzed by immunoblot.

siRNA knockdown {#s4-12}
---------------

3.5 × 10^5^ HEK293Ts were plated in 2 ml antibiotic free media per well in six-well plates and reverse transfected with 5 μl 20 μM siRNA in 500 μl OptiMEM-I and 5 μl of Lipofectamine RNAiMAX for 48--96 hr until harvest for flow cytometry or SDS-PAGE and immunoblot analysis. siRNA duplexes against human AP-2μ were purchased from ThermoFisher Dharmacon RNAi Technologies (Waltham, MA) with the following sequence: 5′-GGAGAACAGUUCUUGCGGC-3′ and with the following conditions: ON-TARGET - Enhanced Antisense Loading, Standard (A4), UU added to 3′ end. Control siRNA (ON-TARGETplus Non-targeting siRNA \#1) was purchased from Dharmacon.

Yeast two-hybrid interaction {#s4-13}
----------------------------

Cells of an overnight culture (2.5 ml) of yeast strain PJ69-4a in YPD media grown at 30°C were washed in H~2~O and mixed sequentially with the following: 50% PEG-3500 (Sigma-Aldrich), 10 mM lithium acetate in Tris-EDTA (TE) (pH 7.5), denatured salmon sperm DNA (Invitrogen) and 100 ng of plasmid constructs, then mixed. Yeast were incubated for 30 min at 30°C and heat-shocked for 15 min at 42°C. Cells were centrifuged, resuspended in H~2~O, and spread on YNB plates with --Trp --Leu dropout mix. Liquid cultures in Trp-Leu broth were grown at 30°C overnight. Cells were normalized to 1.0 OD and 1:10 dilutions made. 4 μl of each dilution was plated on --Trp--Leu--His, and --Trp--Leu--Ade at 30°C. YPD, YNB and dropout mixtures purchased from Sunrise Science. Growth on --Trp--Leu--His or --Trp--Leu--Ade plates was recorded at day 3.

In vitro COPII budding assay {#s4-14}
----------------------------

COPII vesicle formation was performed as described previously ([@bib31]; [@bib41]). In brief, RAW264 cells grown in 10 × 10-mm plates or COS7 cells grown in 6 × 100-mm plates were washed in PBS, removed from plates with trypsin, and washed again in PBS containing 10 μg/ml soybean trypsin inhibitor. Cells were permeablized with 40 μg/ml digitonin for 5 min in ice-cold KHM buffer (110 mM KOAc, 20 mM Hepes pH 7.2 and 2 mM Mg(OAC)~2~) and washed and resuspended in 100 μl KHM. Each reaction contained KHM and where indicated an ATP regenerating system (40 mm creatine phosphate, 0.2 mg/ml creatine phosphokinase, and 1 mm ATP), 0.2 mm GTP, and rat liver cytosol (prepared as described previously; [@bib31]). Reactions were incubated at 30°C for 60 min. A 75-μl aliquot of the vesicle fraction was separated from the donor microsomal fraction by centrifugation at 14,000×*g* for 20 min at 4°C. Donor fraction was lysed in 75 μl of Buffer C (10 mm Tris--HCl \[pH 7.6\], 100 mm NaCl, 10% \[w/v\] SDS plus protease inhibitor mixture). The vesicles were collected by centrifugation at 50,000 rpm at 4°C in a Beckman TLA100 rotor for 30 min. Isolated vesicles were lysed in 20 μl of Buffer C. Donor membrane (20% total) and isolated vesicles (75% of total) were separated by SDS-PAGE and analyzed by immunoblotting.
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eLife posts the editorial decision letter and author response on a selection of the published articles (subject to the approval of the authors). An edited version of the letter sent to the authors after peer review is shown, indicating the substantive concerns or comments; minor concerns are not usually shown. Reviewers have the opportunity to discuss the decision before the letter is sent (see [review process](http://www.elifesciences.org/the-journal/review-process)). Similarly, the author response typically shows only responses to the major concerns raised by the reviewers.

Thank you for choosing to send your work entitled "Unc93b1 mediates differential trafficking of TLR7 and TLR9" for consideration at *eLife*. Your article has been evaluated by a Senior editor and 3 reviewers, one of whom is a member of our Board of Reviewing Editors.

The Reviewing editor and the other reviewers discussed their comments before we reached this decision, and the Reviewing editor has assembled the following comments based on the reviewers\' reports.

This is an excellent study providing novel insights into the mechanisms of differential trafficking of TLR7 and TLR9 by the multipass transmembrane protein Unc93b1. The study will have general impact in immunology and cell biology. On the basis of enthusiastic comments by the Reviewing editor and two other reviewers, we will be happy to accept this paper for publication in *eLife*, provided that the authors address the minor issues raised by the reviewers:

1\) A striking finding of this study is the differential use of the Unc93B/AP-2 trafficking pathway by TLR9 and TLR7. The authors suggest that TLR7 can direct itself to endosomes from the golgi through interactions with AP-4 subunits. Is this a common feature of the several TLRs that bind to Unc93B? If yeast 2-hybrid analyses are performed with other endosomal TLRs, are there other examples of TLR-AP4 interactions, or is TLR7 unique?

2\) The authors make the intriguing suggestion that Unc93B binds to a single TLR at a time. This model predicts that at least five different complexes of Unc93B exist in cells (Unc-TLR9 complexes, Unc-TLR7 complexes, etc). If this is true, then immunoprecipitation assays with TLR7 should not be able to co-purify TLR9, while Unc93B pulldowns should isolate both TLR7 and TLR9. The authors are encouraged to perform these assays.

3\) In Figure 7, the schematic figure indicates the role of AP-1 in transfer of TLR9 from Golgi to the plasma membrane. However, we could not find data for this in the study. Can the authors clarify this?
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Author response

*1) A striking finding of this study is the differential use of the Unc93B/AP-2 trafficking pathway by TLR9 and TLR7. The authors suggest that TLR7 can direct itself to endosomes from the golgi through interactions with AP-4 subunits. Is this a common feature of the several TLRs that bind to Unc93B? If yeast 2-hybrid analyses are performed with other endosomal TLRs, are there other examples of TLR-AP4 interactions, or is TLR7 unique*?

To address whether other UNC93B1-dependent TLRs require AP-2 versus AP-4 to reach endosomes, we examined whether signaling is affected in macrophages expressing the UNC93B1-Y539A mutant, which fails to recruit AP-2. As shown in our new Figure 7A, the response to TLR13 ligands is unaffected in these cells, suggesting that TLR13 does not require the UNC93B1/AP-2 pathway for its function. Additionally, we present biochemical evidence that TLR13 trafficking in UNC93B1-Y539A mutant cells is unimpaired (Figure 7B). This result suggests that TLR13 (like TLR7) may utilize AP-4 for Golgi to endosome trafficking, although we do not yet have any direct evidence for this conclusion.

We also tested how responses to TLR3 (PolyI:C) and TLR11 (profilin and flagellin) ligands were affected by the UNC93B1-Y539A mutant. Unfortunately, we were unable to detect responses to TLR3 and TLR11 ligands in macrophages, even when we ectopically expressed TLR11. However, we were able to examine TLR11 and TLR12 trafficking in UNC93B1-Y539A mutant cells and found that the trafficking of these receptors is also unaffected by disruption of the UNC93B1/AP-2 pathway (Figure 7C, D).

As suggested by the reviewers, we have also tried to detect interactions between the cytosolic domains of other endosomal TLRs and the μ subunit of AP-4 using the yeast 2-hybrid (Y2H) assay. We failed to detect any interactions between AP-4 and TLR3, TLR9, TLR11, or TLR13. While this result could support the conclusion that trafficking of TLR3, TLR11, and TLR13 is distinct from trafficking of TLR7, we are hesitant to leap to this conclusion. Our primary concern is that, for reasons that remain unclear, TLR cytosolic domains do not behave equivalently in Y2H assays. For example, Brown et al have reported that the TLR9 cytosolic domain fails to interact with MyD88 by Y2H, while TLR2, TLR5, TLR7, and TLR8 do interact with MyD88 (see Brown et al, EJI, 2006). We have experienced the same problems with the TLR9 cytosolic domain, which is why we did not include Y2H data for TLR9, and suspect that TLR3, TLR11, and TLR13 have similar limitations. Therefore, we cannot rule out that lack of interaction between TLR3, TLR11, or TLR13 (or TLR9 for that matter) and AP-4 is due to a technical limitation of the Y2H assay for these TLRs. For this reason, we have relied on the functional assays that we discussed previously. We would prefer to omit the AP-4 Y2H interaction data from our manuscript due to these technical issues, but we have included the results below for the benefit of the reviewers. \[Editors\' note: the authors have agreed to make the results available in the author response, with the caveats described above.\]Author response image 1.Results from a yeast two-hybrid assay testing for interaction between the AP-4μ subunit and the C-terminal cytosolic region of TLR3, 7, 9, 11, 13.Growth on --His--Trp-- Leu plates (--His) indicates interaction. Growth on --Trp--Leu plates (+His) serves as a control.

*2) The authors make the intriguing suggestion that Unc93B binds to a single TLR at a time. This model predicts that at least five different complexes of Unc93B exist in cells (Unc-TLR9 complexes, Unc-TLR7 complexes, etc). If this is true, then immunoprecipitation assays with TLR7 should not be able to co-purify TLR9, while Unc93B pulldowns should isolate both TLR7 and TLR9. The authors are encouraged to perform these assays*.

We have performed these biochemical experiments and include these data in our new Figure 8. As predicted by the model, immunoprecipitation of TLR7 or TLR9 does precipitate UNC93B1, but does not precipitate the other receptor.

*3) In Figure 7, the schematic figure indicates the role of AP-1 in transfer of TLR9 from Golgi to the plasma membrane. However, we could not find data for this in the study. Can the authors clarify this*?

Including AP-1 in the schematic was a mistake. While we think it is possible that AP-1 mediates this step, we do not have evidence for or against this possibility. We have corrected the schematic (Figure 9) to more accurately reflect our current knowledge.

Unrelated to the three points raised by the reviewers, we have also included additional evidence that AP-4 is involved in TLR7 trafficking to endosomes. In our original submission we described a mutation in TLR7, Y892A that disrupts AP-4 interaction. This mutant receptor no longer responds to TLR7 ligands. In this revised manuscript we now show that this receptor has a substantial reduction in ectodomain processing, further supporting the conclusion that failure to recruit AP-4 leads to reduced TLR7 trafficking to endosomes (Figure 6H).
